Invasive group A streptococcal disease

Infectious Agents and Disease

Volumn 5, Issue 3, 1996, Pages 157-166

  Stevens, Dennis L ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Boise VA Medical Center   (United States)

Author keywords

Clinical features; Demographic features; Group A streptococcal infection; Necrotizing fasciitis; Pathogenesis; Streptococcal toxic shock syndrome; Treatment

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL TOXIN; CLINDAMYCIN; ERYTHROMYCIN; EXOTOXIN; PENICILLIN G;

ANTIBIOTIC THERAPY; BACTERIAL VIRULENCE; HUMAN; MYOSITIS; NECROTIZING FASCIITIS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SCARLET FEVER; STREPTOCOCCUS GROUP A; STREPTOCOCCUS INFECTION; TOXIC SHOCK SYNDROME;

AGE FACTORS; ANIMALS; ANTI-BACTERIAL AGENTS; BACTEREMIA; CLINDAMYCIN; ERYTHROMYCIN; FASCIITIS, NECROTIZING; HUMANS; PENICILLIN RESISTANCE; PENICILLINS; SHOCK, SEPTIC; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES;

EID: 0030013033     PISSN: 10562044     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Adams EM, Gudmundsson S, Yocum DE, Haselby RC, Craig WA, Sundstrom WR. Streptococcal myositis. Arch Intern Med 1985;145:1020-3.
2. Barnham M. Invasive streptococcal infections in the era before the acquired immune deficiency syndrome: a 10 years' compilation of patients with streptococcal bacteraemia in North Yorkshire. J Infect 1989;18:231-48.
3. Barry W, Hudgins L, Donta S, Pesanti E. Intravenous immunoglobulin therapy for toxic shock syndrome. JAMA 1992;267:3315-6.
4. Bartter T, Dascal A, Carroll K, Curley FJ. "Toxic strep syndrome": manifestation of group A streptococcal infection. Arch Intern Med 1988;148:1421-4.
5. Braunstein H. Characteristics of group A streptococcal bacteremia in patients at the San Bernardino County Medical Center. Rev Infect Dis 1991;13:8-11.
6. Brook I. Role of beta-lactamase-producing bacteria in the failure of penicillin to eradicate group A streptococci. Pediatr Infect Dis 1985;4:491-5.
7. Bullowa JGM, Wishik SM. Complications of varicella. I. Their occurrence among 2,534 patients. Am J Dis Child 1935;49:923-6.
8. Eagle H. Experimental approach to the problem of treatment failure with penicillin. I. Group A streptococcal infection in mice. Am J Med 1952;13:389-99.
9. Fast DJ, Schlievert PM, Nelson RD. Toxic shock syndrome-associated staphylococcal and streptococcal pyrogenic toxins are potent inducers of tumor necrosis factor production. Infect Immun 1989;57:291-4.
10. Francis J, Warren RE. Streptococcus pyogenes bacteraemia in Cambridge: a review of 67 episodes. Q J Med 1988;256:603-13.
11. Gatanaduy AS, Kaplan EL, Huwe BB, McKay C, Wannamaker LW. Failure of penicillin to eradicate group A streptococci during an outbreak of pharyngitis. Lancet 1980;2:498-502.
12. Gaworzewska ET, Coleman G. Correspondence: group A streptococcal infections and a toxic shock-like syndrome. N Engl J Med 1989;321(22):1546.
13. Gemmell CG, Peterson PK, Schmeling D, et al. Potentiation of opsonization and phagocytosis of Streptococcus pyogenes following growth in the presence of clindamycin. J Clin Invest 1981;67:1249-56.
14. Greenberg RN, Willoughby BG, Kennedy DJ, Otto TJ, Mc-Millian R, Bloomster TG. Hypocalcemia and "toxic" syndrome associated with streptococcal fasciitis. South Med J 1983;76(7):916-8.
15. Hackett SP, Schlievert PM, Stevens DL. Cytokine production by human mononuclear cells in response to streptococcal exotoxins [Abstract]. Clin Res 1991;39:189A.
16. Hackett SP, Stevens DL. Streptococcal toxic shock syndrome: synthesis of tumor necrosis factor and interleukin-1 by monocytes stimulated with pyrogenic exotoxin A and streptolysin O. J Infect Dis 1992;165:879-85.
17. Holm S. Fatal group A streptococcal infections [Abstract]. Presented at the 89th Meeting of the American Society of Microbiology. New Orleans, 1989.
18. Hribalova V. Streptococcus pyogenes and the toxic shock syndrome. Ann Intern Med 1988;108:772.
19. Jackson MA, Burry VF, Olson LC. Multisystem group A beta-hemolytic streptococcal disease in children. Rev Infect Dis 1991;13(5):783-8.
20. Kim KS, Kaplan EL. Association of penicillin tolerance with failure to eradicate group A streptococci from patients with pharyngitis. J Pediatr 1985;107:681-4.
21. Kohler W. Streptococcal toxic shock syndrome. Zbl Bakt 1990;272:257-64.
22. Kotb M, Tomai M, Majumdar G, Walker J, Beachey EH. Cellular and biochemical responses of human T lymphocytes stimulated with streptococcal M protein [Abstract L77]. Presented at the 11th Lancefield International Symposium on Streptococcal Diseases. Siena. Italy, 1990.
23. Lancefield RC. Current knowledge of type specific M antigens of group A streptococci. J Immunol 1962;89:307-13.
24. Martin PR, Hoiby EA. Streptococcal serogroup A epidemic in Norway 1987-1988. Scand J Infect Dis 1990:22:421-9.
25. Meleney FL. Hemolytic streptococcus gangrene. Arch Surg 1924;9:317-64.
26. Mollick JA, Rich RR. Characterization of a superantigen from a pathogenic strain of Streptococcus pyogencs. Clin Res 1991;39(2):213A.
27. Musser JM, Hauser AR, Kim MH, Schlievert PM, Nelson K, Selander RK. Streptococcus pyogenes causing toxic-shock-like syndrome and other invasive diseases: clonal diversity and pyrogenic exotoxin expression. Proc Natl Acad Sci USA 1991;88:2668-72.
28. Nather A, Wong FY, Balasubramaniam P, Pang M. Streptococcal necrotizing myositis, a rare entity: a report of two cases. Clin Orthop 1987;215:206-11.
29. Schwartz B, Facklam RR, Brieman RF. Changing epidemiology of Group A streptococcal infection in the U.S.A. Lancet 1990;336:1167-71.
30. Stevens DL. Invasive group A streptococcus infections. Clin Infect Dis 1992;14:2-13.
31. Stevens DL. Invasive group A streptococcal infections: the past, present and future. Pediatr Infect Dis J 1994;13:561-6.
32. Stevens DL, Bryant AE, Hackett SP. Antibiotic effects on bacterial viability, toxin production, and host response. Clin Infect Dis 1995;20:8154-7.
33. Stevens DL, Bryant AE, Van S. Invasive group A streptococcal infection: new concepts in antibiotic treatment. Int J Antimicrob Agents 1994;4:297-301.
34. Stevens DL, Gibbons AE, Bergstrom R, Winn V. The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J Infect Dis 1988;158:23-8.
35. Stevens DL, Maier KA, Mitten JE. Effect of antibiotics on toxin production and viability of Clostridium perfringens. Antimicrob Agents Chemother 1987;31:213-8.
36. Stevens DL, Musher DM, Watson DA, et al. Spontaneous, nontraumatic gangrene due to Clostridium septicum. Rev Infect Dis 1990:12(2):286-96.
37. Stevens DL, Tanner MH, Winship J, et al. Reappearance of scarlet fever toxin A among streptococci in the Rocky Mountain West: Severe group A streptococcal infections associated with a toxic shock-like syndrome. N Engl J Med 1989;321(1):1-7.
38. Stevens DL, Van S, Bryant AE. Penicillin binding protein expression at different growth stages determines penicillin efficacy in vitro and in vivo: an explanation for the inoculum effect. J Infect Dis 1993;167:1401-5.
39. Svane S. Peracute spontaneous streptococcal myositis: a report on two fatal cases with review of literature. Acta Chir Scand 1971;137:155-63.
40. The Working Group on Severe streptococcal Infections. Defining the group A streptococcal toxic shock syndrome: rationale and consensus definition. JAMA 1993;269(3):390-1.
41. Thomas JC, Carr SJ, Fujioka K, Waterman SH. Community-acquired group A streptococcal deaths in Los Angeles county. J Infect Dis 1989;160(6):1086-7.
42. Wannamaker LW, Rammelkamp CH Jr., Denny FW, et al. Prophylaxis of acute rheumatic fever by treatment of the preceding streptococcal infection with various amounts of depot penicillin. Am J Med 1951;10:673-95.
43. Weaver GH, Scarlet fever. In: Abt IA, ed. Pediatrics. Philadelphia: W.B. Saunders Co., 1925:298-362.
44. Wheeler MC, Roe MH, Kaplan EL, Schlievert PM, Todd JK. Outbreak of group A streptococcus septicemia in children: clinical, epidemiologic, and microbiological correlates. JAMA 1991;266(4):533-7.
45. Yan S, Bohach GA, Stevens DL. Persistent acylation of high-molecular weight penicillin binding proteins by penicillin induces the post antibiotic effect in Streptococcus pyogenes. J Infect Dis 1994;170:609-14.
46. Yan S, Mendelman PM, Stevens DL. The in vitro antibacterial activity of ceftriaxone against Streptococcus pyogenes is unrelated to penicillin-binding protein 4. FEMS Microbiol Lett 1993;110:313-8.
47. Yoder EL, Mendez J, Khatib R. Spontaneous gangrenous myositis induced by Streptococcus pyogenes: case report and review of the literature. Rev Infect Dis 1987;9(2):382-5.
48. Yong JM. Letter. Lancer 1994;343:1427.